To include your compound in the COVID-19 Resource Center, submit it here.

Alder receives rights to eptinezumab IP from Teva

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) granted Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) rights to IP related to eptinezumab (IV ALD403). Alder also announced that the migraine prevention candidate

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE